

Talia Cohen Solal, Ph.D. is the CEO and Co-founder of NeuroKaire, which has developed a blood test to predict which antidepressant is best for each patient. During her academic career across Oxford, UCL and Columbia University, Talia led the development neural models of mental illnesses for personalised forms of diseases and developed and patented new drug screening methodologies and compounds. She then led the scientific program as Principle Scientist at Pairnomix in Minneapolis, a White-House Endorsed early-stage company developing personalized medicine tools for rare-genetic diseases. As CEO of NeuroKaire, she has won the top prizes in the MassChallenge Accelerator, Israel BrainTech and EY Digital Health. As CEO of NeuroKaire she has raised over \$25M, won EIC and IIA funding, and led the technology from bench to bedside, bringing a research technology to a clinically validated, regulatory approved, IP protected commercial technology.